1. Volume 19, Issue 3, Pages 145-153 (March 2017)
Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer 
Ki Cheong Park, Seok-Mo Kim, Jeong Yong Jeon, Bup-Woo Kim, Hyeung Kyoo Kim, Ho Jin Chang, Yong Sang Lee, Soo Young Kim, Seung Hoon Choi, Cheong Soo Park, Hang-Seok Chang 
Neoplasia 
Volume 19, Issue 3, Pages (March 2017)
DOI: /j.neo
Copyright © 2016 The Authors Terms and Conditions

2. Figure 1
Combination of HNHA and sorafenib suppressed ATC cell proliferation more efficiently than either agent alone. Cell viability and proliferation assay of HNHA and sorafenib combined and HNHA and sorafenib alone in ATC cells (8505C, A and B; SNU-80, C and D; GSA1, E and F). Points indicate mean % of the value observed in the solvent-treated control. All experiments were repeated at least 3 times. The data represent the mean±SD. Experiments were repeated at least 3 times with similar results. * P<.05 vs. control, ** P<.01 vs. control, *** P<.005 vs. control.
Neoplasia  , DOI: ( /j.neo )
Copyright © 2016 The Authors Terms and Conditions

3. Figure 2
Combination of HNHA and sorafenib induced cell cycle arrest and endoplasmic reticulum stress in ATC cells more potently than either agent alone. Immunoblot analysis of the indicated cell lines following exposure to the HNHA and sorafenib combination or each agent singly. The HNHA and sorafenib combination potently induced the expression of cell cycle arrest proteins and reduced the expression of positive regulators of the cell cycle (A). 8505C, SNU 80, and GSA1 were exposed to the indicated inhibitors for 24 h prior to the analysis of the expression of GRP78, ATF4, CHOP, PERK, p-PERK, eIF2α, and p-eIF2α (markers of endoplasmic reticulum stress) by immunoblot analysis (B). Cells were exposed to the indicated inhibitors, harvested, and stained with propidium iodide before analysis by flow cytometry and FlowJo v8 software (C).
Neoplasia  , DOI: ( /j.neo )
Copyright © 2016 The Authors Terms and Conditions

4. Figure 3
Combination of HNHA and sorafenib significantly induced apoptotic death in ATC cells. Immunoblot analyses suggested that the indicated inhibitors increased the levels of apoptotic proteins and reduced those of anti-apoptotic proteins in ATC cells (A). TUNEL assay of ATC cells; TUNEL-positive (apoptotic) cells are indicated (×400) (B, 5805C; C, SNU-80; and D, GSA1).
Neoplasia  , DOI: ( /j.neo )
Copyright © 2016 The Authors Terms and Conditions

5. Figure 4
Combination of HNHA and sorafenib produced antitumor effects in ATC cell xenografts in vivo. Athymic nude mice with established tumors were treated with the indicated inhibitors. Data represent the mean tumor volumes. HNHA and sorafenib combination therapy induced more potent inhibition of tumor progression than did HNHA or sorafenib alone, resulting in the maximum prolongation of survival in mice with ATC (8505C, A–D; SNU-80, E–H; and GSA1, I–L) xenografts (n=10 mice/group) (A, E, and I). “No tumor + HNHA + sorafenib” indicates HNHA and sorafenib combination-treated mice with no xenograft; no evidence of systemic toxicity or treatment-related death was found in HNHA and sorafenib combination-treated groups (B, F, and J). The compounds had no significant effect on mouse body weight (C, G, and K). Weights of the dissected tumors (D, H, and L). Immunoblot analysis of total proteins isolated from the tumors (M). * P<.05 vs. control, ** P<.01 vs. control, *** P<.005 vs. control.
Neoplasia  , DOI: ( /j.neo )
Copyright © 2016 The Authors Terms and Conditions

6. Figure 5
HNHA and sorafenib combination therapy significantly reduced tumor Bcl-2 expression. Immunohistochemical analysis of the Bcl-2 protein levels in paraffin-embedded tumor tissues from mice with ATC xenografts. Synergistic activity of the HNHA and sorafenib combination induced more potent inhibition of tumor Bcl-2 expression than HNHA or sorafenib did alone. MetaMorph 4.6 image-analysis software was used to quantify Bcl-2 immunostaining. * P<.05; ** P<.01; *** P<.005 for the comparison with the control.
Neoplasia  , DOI: ( /j.neo )
Copyright © 2016 The Authors Terms and Conditions